Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$58.35B |
$445.07
+3.55%
|
|
ZTS
Zoetis Inc.
Zoetis employs monoclonal antibodies for OA pain and dermatology therapies (e.g., Librela, Solensia, Cytopoint), defining a core Monoclonal Antibody Therapeutics product line.
|
$56.59B |
$127.69
-0.16%
|
|
BDX
Becton, Dickinson and Company
BD is a global medical devices & biometrics company with multiple device-based offerings and biometric sensing capabilities.
|
$55.58B |
$193.94
-0.79%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$54.87B |
$917.91
-0.00%
|
|
EW
Edwards Lifesciences Corporation
Core product category including SAPIEN/TAVR, Pascal, Evoque, and SAPIEN M3 used in structural heart interventions.
|
$50.93B |
$86.75
-0.07%
|
|
CAH
Cardinal Health, Inc.
Nuclear medicine radiopharmaceuticals distribution and related imaging agents.
|
$50.90B |
$213.13
-0.28%
|
|
MET
MetLife, Inc.
Disability Insurance is part of MetLife's product suite within employee benefits.
|
$50.76B |
$76.33
+0.77%
|
|
ROP
Roper Technologies, Inc.
Verathon bronchoscopes and other medical devices place Roper squarely in Medical Devices & Biometrics.
|
$48.00B |
$446.29
-0.03%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$46.03B |
$14.52
+0.10%
|
|
AME
AMETEK, Inc.
Paragon Medical alignment indicates AMETEK provides Medical Device Components as part of its Electromechanical Group.
|
$45.33B |
$196.27
-0.48%
|
|
HLN
Haleon plc
Panadol and other analgesics position Haleon in OTC Pain Relief & Analgesics.
|
$44.57B |
$9.76
-0.61%
|
|
A
Agilent Technologies, Inc.
Agilent provides diagnostic instrument platforms used in life sciences and clinical diagnostics.
|
$43.85B |
$154.34
-1.82%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$43.23B |
$204.49
-2.17%
|
|
PAYX
Paychex, Inc.
Health Insurance; PEO insurance solutions for employees.
|
$40.13B |
$111.41
-0.62%
|
|
PUK
Prudential plc
Health insurance offerings are a central pillar of Prudential's business strategy and geographic footprint.
|
$39.62B |
$28.78
+1.84%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$39.41B |
$231.92
|
|
BBD
Banco Bradesco S.A.
Health insurance products within Bradesco's Insurance Group.
|
$39.16B |
$3.69
+4.10%
|
|
ALC
Alcon Inc.
Alcon directly designs and manufactures ophthalmology devices including intraocular lenses and surgical platforms.
|
$39.16B |
$79.19
-0.59%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$37.52B |
$340.81
+1.68%
|
|
RMD
ResMed Inc.
CPAP devices and masks are core ResMed medical devices.
|
$37.34B |
$255.06
-0.29%
|
|
GEHC
GE HealthCare Technologies Inc.
GE HealthCare's core product portfolio centers on medical imaging devices and imaging systems (CT/MR/PET).
|
$36.81B |
$80.62
+0.83%
|
|
VTR
Ventas, Inc.
Healthcare Services & Facilities captures ownership/operation of healthcare facilities including senior housing and outpatient spaces.
|
$36.39B |
$80.09
+0.82%
|
|
SLF
Sun Life Financial Inc.
Health insurance offerings (including group health solutions and stop-loss) are key to Sun Life's business.
|
$33.78B |
$58.71
-0.73%
|
|
KVUE
Kenvue Inc.
Kenvue directly manufactures and sells OTC analgesics (e.g., Tylenol).
|
$33.05B |
$17.21
+1.06%
|
|
NTRA
Natera, Inc.
Natera's Signatera MRD and Signatera Genome tests are liquid biopsy assays using cfDNA to detect minimal residual disease in cancer, a core liquid biopsy product.
|
$32.54B |
$237.16
+0.28%
|
|
HUM
Humana Inc.
Humana's core revenue and offerings are health insurance products and related services for individuals, employers, and government programs.
|
$29.59B |
$245.94
+3.39%
|
Showing page 3 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
